US 12,076,387 B2
Vaccines comprising mutant attenuated influenza viruses
Shinji Watanabe, Tokyo (JP); Tokiko Watanabe, Osaka (JP); and Yoshihiro Kawaoka, Middleton, WI (US)
Assigned to Wisconsin Alumni Research Foundation (WARF), Madison, WI (US)
Filed by Wisconsin Alumni Research Foundation (WARF), Madison, WI (US)
Filed on Apr. 13, 2021, as Appl. No. 17/229,001.
Application 17/229,001 is a continuation of application No. 16/173,605, filed on Oct. 29, 2018, granted, now 11,007,262.
Application 16/173,605 is a continuation of application No. 13/070,110, filed on Mar. 23, 2011, granted, now 10,130,697.
Claims priority of provisional application 61/316,564, filed on Mar. 23, 2010.
Prior Publication US 2021/0252130 A1, Aug. 19, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61K 2039/5254 (2013.01); A61K 2039/543 (2013.01); C12N 2760/16134 (2013.01)] 35 Claims
 
1. A vaccine comprising an effective amount of a live, attenuated isolated recombinant influenza virus comprising a mutant M viral segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein comprising an extracellular domain or a portion thereof, a deletion of a cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain, wherein the attenuated isolated recombinant influenza virus is a reassortant virus comprising at least six viral segments from a master vaccine strain and at least one viral segment from a strain different from the master vaccine strain, wherein the at least one viral segment from a strain different from the master vaccine strain is HA.